Evidence map›Paper›PMID 26501105›Full record

Trial reportEBioMedicine2015

The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study.

Naohisa Hosomi, Yoji Nagai, Tatsuo Kohriyama, Toshiho Ohtsuki, Shiro Aoki, Tomohisa Nezu, Hirofumi Maruyama, Norio Sunami, Chiaki Yokota, Kazuo Kitagawa and 13 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06649240 (Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke), which is not on this map. Cited by 55 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 13 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06649240 narecruitingstarted 2024, after this paper: background citation

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)

Ran2024Enrolled4,016Registered outcomes7Posted comparisons0ConditionsCardiovascular Diseases, Cholesterol, LDL, Ischemic Stroke, Secondary PreventionArmsPCSK9 inhibitor, Statins and/or Ezetimibe
PMID 31738483PMID 16899775PMID 30558400PMID 18077795PMID 19228842PMID 23899749PMID 26060798PMID 7678184PMID 37236211PMID 34024117other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 13 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. The association of statin therapy and cancer: a meta-analysis.Lipids in health and disease · 2023 · on this map
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. 2018 Guidelines for the management of dyslipidemia.The Korean journal of internal medicine · 2019
    Guideline
  11. Pooled it
  12. Pooled it
  13. Guideline
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

Naohisa HosomiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Yoji NagaiFoundation for Biomedical Research and Innovation Translational Research Informatics Center, Kobe, Japan.
Tatsuo KohriyamaHiroshima City Rehabilitation Hospital, Hiroshima, Japan.
Toshiho OhtsukiStroke Center, Kinki University, Osakasayama, Japan.
Shiro AokiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Tomohisa NezuDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Hirofumi MaruyamaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Norio SunamiDepartment of Neurological Surgery, Matsuyama Shimin Hospital, Matsuyama, Japan.
Chiaki YokotaNational Cerebral and Cardiovascular Center, Suita, Japan.
Kazuo KitagawaDepartment of Neurology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Yasuo TerayamaDepartment of Neurology, Iwate Medical University, Morioka, Japan.
Makoto TakagiDepartment of Neurology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
Setsuro IbayashiSeiai Rehabilitation Hospital, Fukuoka, Japan.
Masakazu NakamuraNational Cerebral and Cardiovascular Center, Suita, Japan.
Hideki OrigasaDivision of Biostatistics and Clinical Epidemiology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Masanori FukushimaFoundation for Biomedical Research and Innovation Translational Research Informatics Center, Kobe, Japan.
Etsuro MoriDepartment of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kazuo MinematsuNational Cerebral and Cardiovascular Center, Suita, Japan.
Shinichiro UchiyamaClinical Research Center, International University of Health and Welfare, Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center, Tokyo, Japan.
Yukito ShinoharaFederation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital, Tokyo, Japan.
Takenori YamaguchiNational Cerebral and Cardiovascular Center, Suita, Japan.
Masayasu MatsumotoDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
J-STARS Collaborators
Hiroshima University · JPNational Cerebral and Cardiovascular Center · JPTranslational Research Informatics Center (Japan) · JPHiroshima Prefectural Rehabilitation Center · JPIwate Medical University · JPKindai University · JPMatsuyama Shimin Hospital · JPSaiseikai Central Hospital · JPSanno Medical Center · JPTachikawa Hospital · JPTohoku University · JPTokyo Women's Medical University · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough statin therapy is beneficial for the prevention of initial stroke, the benefit for recurrent stroke and its subtypes remains to be determined in Asian, in whom stroke profiles are different from Caucasian. This study examined whether treatment with low-dose pravastatin prevents stroke recurrence in ischemic stroke patients.

methodsThis is a multicenter, randomized, open-label, blinded-endpoint, parallel-group study of patients who experienced non-cardioembolic ischemic stroke. All patients had a total cholesterol level between 4.65 and 6.21 mmol/L at enrollment, without the use of statins. The pravastatin group patients received 10 mg of pravastatin/day; the control group patients received no statins. The primary endpoint was the occurrence of stroke and transient ischemic attack (TIA), with the onset of each stroke subtype set to be one of the secondary endpoints. FINDING: Although 3000 patients were targeted, 1578 patients (491 female, age 66.2 years) were recruited and randomly assigned to pravastatin group or control group. During the follow-up of 4.9 ± 1.4 years, although total stroke and TIA similarly occurred in both groups (2.56 vs. 2.65%/year), onset of atherothrombotic infarction was less frequent in pravastatin group (0.21 vs. 0.64%/year, p = 0.0047, adjusted hazard ratio 0.33 [95%CI 0.15 to 0.74]). No significant intergroup difference was found for the onset of other stroke subtypes, and for the occurrence of adverse events.

interpretationAlthough whether low-dose pravastatin prevents recurrence of total stroke or TIA still needs to be examined in Asian, this study has generated a hypothesis that it may reduce occurrence of stroke due to larger artery atherosclerosis.

fundingThis study was initially supported by a grant from the Ministry of Health, Labour and Welfare, Japan. After the governmental support expired, it was conducted in collaboration between Hiroshima University and the Foundation for Biomedical Research and Innovation.

Indexed as

Asian PeopleAgedBrain IschemiaFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsJapanKaplan-Meier EstimateMaleMiddle AgedOutcome Assessment, Health CarePravastatinProportional Hazards ModelsRecurrenceStrokeHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatinAtherothrombotic infarctionCholesterolHemorrhagic strokeIschemic strokeStatin

Identifiers

PMID26501105
PMCPMC4588424
OpenAlexW2097571126

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.